Evidence that lipopolisaccharide may contribute to the cytokine storm and cellular activation in patients with visceral leishmaniasis

PLoS Neglected Tropical Diseases

Volumn 5, Issue 7, 2011, Pages

  Santos Oliveira, Joanna R ^a   Regis, Eduardo G ^a   LealCá, Cássia R B ^b   Cunha, Rivaldo V ^b   BozzaPatrí, Patrícia T ^a   Da Cruz, Alda M ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF MATO GROSSO DO SUL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CD14 ANTIGEN; CD38 ANTIGEN; FATTY ACID BINDING PROTEIN 2; GAMMA INTERFERON; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1; MACROPHAGE MIGRATION INHIBITION FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; PARASITE ANTIGEN; TUMOR NECROSIS FACTOR; CYTOKINE; ISOMERASE; LIPOPOLYSACCHARIDE; MIF PROTEIN, HUMAN;

ADULT; AMASTIGOTE; ARTICLE; BACTERIAL TRANSLOCATION; BIOLOGICAL ACTIVITY; CD4 CD8 RATIO; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE STORM; DISEASE ASSOCIATION; EFFECTOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GRAM NEGATIVE BACTERIUM; HUMAN; IMMUNE STATUS; IMMUNOPATHOGENESIS; IMMUNOREACTIVITY; MALE; MUCOSAL IMMUNITY; NONHUMAN; PERMEABILITY BARRIER; PROTEIN BLOOD LEVEL; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; VISCERAL LEISHMANIASIS; ADOLESCENT; BACTERIUM; BLOOD; IMMUNOASSAY; IMMUNOLOGY; LEISHMANIA; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MIDDLE AGED; PATHOGENICITY;

ADOLESCENT; ADULT; BACTERIA; BACTERIAL TRANSLOCATION; CYTOKINES; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOASSAY; INTRAMOLECULAR OXIDOREDUCTASES; LEISHMANIA; LEISHMANIASIS, VISCERAL; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 79960959727     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001198     Document Type: Article

References (46)

1. Saúde Ministério da, Brasil. Manual de Vigilância e Controle da Leishmaniose Visceral (2009) Available: http://portal.saude.gov.br/portal/arquivos/pdf/manual_leish_visceral_serie_2006.pdf.
2. Saha S, Mondal S, Banerjee A, Ghose J, Bhowmick S, et al. (2006) Immune responses in kala-azar. Indian J Med Res 123: 245-266.
3. Carvalho EM, Teixeira RS, Johnson WD Jr, (1981) Cell-mediated immunity in American visceral leishmaniasis: reversible immunosuppression during acute infection. Infect Immun 33: 498-500.
4. Carvalho EM, Badaró R, Reed SG, Jones TC, Johnson WD Jr, (1985) Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis. J Clin Invest 76: 2066-2069.
5. Carvalho EM, Bacellar O, Barral A, Badaró R, Johnson WD Jr, (1989) Antigen-specific immunosuppression in visceral leishmaniasis is cell mediated. J Clin Invest 83: 860-864.
6. Karp CL, el-Safi SH, Wynn TA, Satti MM, Kordofani AM, et al. (1993) In vivo cytokine profiles in patients with kala-azar: marked elevation of both interleukin-10 and interferon-gamma. J Clin Invest 91: 1644-1648.
7. Peruhype-Magalhães V, Martins-Filho OA, Prata A, Silva LA, Rabello A, et al. (2006) Mixed inflammatory/regulatory cytokine profile marked by simultaneous raise of interferon-gamma and interleukin-10 and low frequency of tumour necrosis factor-alpha(+) monocytes are hallmarks of active human visceral leishmaniasis due to Leishmania chagasi infection. Clin Exp Immunol 146: 124-132.
8. Nylén S, Maurya R, Eidsmo L, Manandhar KD, Sundar S, et al. (2007) Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis. J Exp Med 204: 805-817.
9. Carvalho EM, Bacellar O, Brownell C, Regis T, Coffman R, et al. (1994) Restoration of IFN-γ production and lymphocyte proliferation in visceral leishmaniasis. J Immunol 152: 5949-5956.
10. Caldas A, Favali C, Aquino D, Vinhas V, van Weyenbergh J, et al. (2005) Balance of IL-10 and interferon-gamma plasma levels in human visceral leishmaniasis: implications in the pathogenesis. BMC Infect Dis 5: 113-121.
11. Goto H, Prianti MG, (2009) Immunoactivation and immunopathogeny during active visceral leishmaniasis. Rev Inst Med Trop São Paulo 51: 241-246.
12. Nylén S, Sacks D, (2007) Interleukin-10 and the pathogenesis of human visceral leishmaniasis. Trends Immunol 28: 378-384.
13. Giorgi JV, Hultin LE, McKeating JA, Johnson TD, Owens B, et al. (1999) Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 179: 859-870.
14. Brenchley JM, Schacker TW, Ruff LE, Price DA, Taylor JH, et al. (2004) CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 200: 749-759.
15. Mehandru S, Poles MA, Tenner-Racz K, Horowitz A, Hurley A, et al. (2004) Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 200: 761-770.
16. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, et al. (2006) Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 12: 1365-1371.
17. Caradonna L, Amati L, Magrone T, Pellegrino NM, Jirillo E, et al. (2000) Enteric bacteria, lipopolysaccharides and related cytokines in inflammatory bowel disease: biological and clinical significance. J Endotoxin Res 6: 205-214.
18. Lee PI, Ciccone EJ, Read SW, Asher A, Pitts R, et al. (2009) Evidence for translocation of microbial products in patients with idiopathic CD4 lymphocytopenia. J Infect Dis 199: 1664-1670.
19. Cooke KR, Olkiewicz K, Erickson N, Ferrara JL, (2002) The role of endotoxin and the innate immune response in the pathophysiology of acute graft versus host disease. J Endotoxin Res 8: 441-448.
20. Roger T, David J, Glauser MP, Calandra T, (2001) MIF regulates innate immune responses through modulation of Toll-like receptor 4. Nature 414: 920-924.
21. Lu YC, Yeh WC, Ohashi PS, (2008) LPS/TLR4 signal transduction pathway. Cytokine 42: 145-151.
22. Bacher M, Meinhardt A, Lan HY, Mu W, Metz CN, et al. (1997) Migration inhibitory factor expression in experimentally induced endotoxemia. Am J Pathol 150: 235-246.
23. Nishihira J, Mitsuyama K, (2009) Overview of the role of macrophage migration inhibitory factor (MIF) in inflammatory bowel disease. Curr Pharm Des 15: 2104-2109.
24. Ayoub S, Hickey MJ, Morand EF, (2008) Mechanisms of disease: macrophage migration inhibitory factor in SLE, RA and atherosclerosis. Nat Clin Pract Rheumatol 4: 98-105.
25. Calandra T, Echtenacher B, Roy DL, Pugin J, Metz CN, et al. (2000) Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 6: 164-170.
26. Bozza FA, Gomes RN, Japiassú AM, Soares M, Castro-Faria-Neto HC, et al. (2004) Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis. Shock 22: 309-313.
27. Yamada G, Shijubo N, Takagi-Takahashi Y, Nishihira J, Mizue Y, et al. (2002) Elevated levels of serum macrophage migration inhibitory factor in patients with pulmonary tuberculosis. Clin Immunol 104: 123-127.
28. Assunção-Miranda I, Amaral FA, Bozza FA, Fagundes CT, Sousa LP, et al. (2010) Contribution of macrophage migration inhibitory factor to the pathogenesis of dengue virus infection. FASEB J 24: 218-228.
29. Regis EG, Barreto-de-Souza V, Morgado MG, Bozza MT, Leng L, et al. (2010) Elevated levels of macrophage migration inhibitory factor (MIF) in the plasma of HIV-1-infected patients and in HIV-1-infected cell cultures: a relevant role on viral replication. Virology 399: 31-38.
30. Lieberman JM, Sacchettini J, Marks C, Marks WH, (1997) Human intestinal fatty acid binding protein: report of an assay with studies in normal volunteers and intestinal ischemia. Surgery 121: 335-342.
31. Relja B, Szermutzky M, Henrich D, Maier M, de Haan JJ, et al. (2010) Intestinal-FABP and liver-FABP: novel markers for severe abdominal injury. Acad Emerg Med 17: 729-35.
32. Derikx JP, Vreugdenhil AC, Van den Neucker AM, Grootjans J, van Bijnen AA, et al. (2009) A pilot study on the noninvasive evaluation of intestinal damage in celiac disease using I-FABP and L-FABP. J Clin Gastroenterol 43: 727-733.
33. Barral-Netto M, Barral A, Santos SB, Carvalho EM, Badaro R, et al. (1991) Soluble IL-2 receptor as an agent of serum-mediated suppression in human visceral leishmaniasis. J Immunol 147: 281-284.
34. Soares NM, Ferraz TP, Nascimento EG, Carvalho EM, Pontes-de-Carvalho L, (2006) The major circulating immunosuppressive activity in American visceral leishmaniasis patients is associated with a high-molecular weight fraction and is not mediated by IgG, IgG immune complexes or lipoproteins. Microb Pathog 40: 254-260.
35. Nery Costa CH, Werneck GL, Lamounier D, Holanda TA, Aguiar GB, et al. (2010) Is severe visceral leishmaniasis a systemic inflammatory response syndrome? - a case control study. Rev Soc Bras Med Trop 43: 386-395.
36. Cenini P, Berhe N, Hailu A, McGinnes K, Frommel D, (1993) Mononuclear cell subpopulations and cytokine levels in human visceral leishmaniasis before and after chemotherapy. J Infect Dis 168: 986-993.
37. Hailu A, van Baarle D, Knol GJ, Berhe N, Miedema F, et al. (2005) T cell subset and cytokine profiles in human visceral leishmaniasis during active and asymptomatic or sub-clinical infection with Leishmania donovani. Clin Immunol 117: 182-191.
38. Benito JM, Zabay JM, Gil J, Bermejo M, Escudero A, et al. (1997) Quantitative alterations of the functionally distinct subsets of CD4 and CD8 T lymphocytes in asymptomatic HIV infection: changes in the expression of CD45RO, CD45RA, CD11b, CD38, HLA-DR, and CD25 antigens. J Acquir Immune Defic Syndr Hum Retrovirol 14: 128-135.
39. Calandra T, Bernhagen J, Mitchell RA, Bucala R, (1994) The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 179: 1895-1902.
40. Bozza FA, Salluh JI, Japiassu AM, Soares M, Assis EF, et al. (2007) Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Crit Care 11: R49.
41. Barral-Netto M, Badaró R, Barral A, Almeida RP, Santos SB, et al. (1991) Tumor necrosis factor (cachectin) in human visceral leishmaniasis. J Infect Dis 163: 853-857.
42. Sundar S, Reed SG, Sharma S, Mehrotra A, Murray HW, (1997) Circulating T helper 1 (Th1) cell- and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis. Am J Trop Med Hyg 56: 522-525.
43. Calandra T, Roger T, (2003) Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 3: 791-800.
44. Muigai R, Gatei DG, Shaunak S, Wozniak A, Bryceson AD, (1983) Jejunal function and pathology in visceral Leishmaniasis. Lancet 2: 476-479.
45. Baba CS, Makharia GK, Mathur P, Ray R, Gupta SD, et al. (2006) Chronic diarrhea and malabsorption caused by Leishmania donovani. Indian J Gastroenterol 25: 309-310.
46. Hicks L, Kant P, Tay PH, Vincini V, Schuster H, et al. (2009) Visceral leishmaniasis presenting with intestinal failure: a case report and literature review. Eur J Gastroenterol Hepatol 21: 117-122.